Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.11
-0.00 (-2.15%)
Market open: Aug 12, 2026, 12:17 PM EDT
0.11
-0.00 (-1.43%)
Previous after-hours: Aug 11, 2026, 7:59 PM EDT
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
| Name | Position |
|---|---|
| Dr. Beom Kyu Choi | Chief Technology Officer & Member of Scientific Advisory Board |
| Dr. Byong Chul Yoo Ph.D. | Chief Science Officer & Member of Scientific Advisory Board |
| Mr. Chris Kim J.D., L.L.M. | CEO, Chairman & President |
| Mr. Scott Dam | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-04 | 8-K | tm2622207d1_8k.htm |
| 2026-07-30 | 8-K | tm2621658d1_8k.htm |
| 2026-07-24 | 8-K | tm2621298d1_8k.htm |
| 2026-07-13 | DEF 14A | tm264954-2_def14.htm |
| 2026-07-06 | 8-K | tm2619730d1_8k.htm |
| 2026-06-30 | PRE 14A | tm264954-1_pre14a.htm |
| 2026-06-24 | S-1 | limn-20260331xs1.htm |
| 2026-06-18 | D | |
| 2026-06-03 | 8-K | tm2616851d1_8k.htm |
| 2026-05-27 | 8-K | tm2615785d1_8k.htm |